AR060690A1 - Polimeros que contienen magnesio para la hiperfosfatemia - Google Patents

Polimeros que contienen magnesio para la hiperfosfatemia

Info

Publication number
AR060690A1
AR060690A1 ARP060104871A ARP060104871A AR060690A1 AR 060690 A1 AR060690 A1 AR 060690A1 AR P060104871 A ARP060104871 A AR P060104871A AR P060104871 A ARP060104871 A AR P060104871A AR 060690 A1 AR060690 A1 AR 060690A1
Authority
AR
Argentina
Prior art keywords
magnesium
pharmaceutical composition
pharmaceutically acceptable
aliphatic amine
hyperphosphatemia
Prior art date
Application number
ARP060104871A
Other languages
English (en)
Inventor
Chad C Huval
Pradeep K Dhal
Stephen Randall Holmes-Farley
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR060690A1 publication Critical patent/AR060690A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe una composicion farmacéutica consistente en un polímero de amina alifática o una sal farmacéuticamente aceptable del mismo y un compuesto de magnesio farmacéuticamente aceptable que contiene un ion magnesio. Se describe también un método de tratamiento de la hiperfosfatemia en un paciente. El método consiste en la etapa de administracion al sujeto de una cantidad efectiva de la composicion farmacéutica descrita. Reivindicacion 2: La composicion farmacéutica de la reivindicacion 1, donde el compuesto de magnesio es seleccionado entre el grupo consistente en oxido de magnesio, hidroxido de magnesio, carbonato de magnesio, formiato de magnesio y una combinacion de éstos. Reivindicacion 4: La composicion farmacéutica de la reivindicacion 1, donde el polímero de amina alifática contiene una o más unidades repetitivas representadas por una formula estructural seleccionada entre (1) a (6), o una sal de las mismas, donde: y y z son independientemente cero o un numero entero de uno a diez; R, R1, R2, y R3, independientemente, son H, un grupo alquilo substituido o no substituido o un grupo arilo y X es un contraion negativamente intercambiable.
ARP060104871A 2005-11-08 2006-11-07 Polimeros que contienen magnesio para la hiperfosfatemia AR060690A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73459305P 2005-11-08 2005-11-08

Publications (1)

Publication Number Publication Date
AR060690A1 true AR060690A1 (es) 2008-07-10

Family

ID=37888157

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104871A AR060690A1 (es) 2005-11-08 2006-11-07 Polimeros que contienen magnesio para la hiperfosfatemia

Country Status (8)

Country Link
US (1) US20090162314A1 (es)
EP (1) EP1945196A2 (es)
JP (1) JP2009514966A (es)
CN (1) CN101304739A (es)
AR (1) AR060690A1 (es)
BR (1) BRPI0618352A2 (es)
CA (1) CA2626734A1 (es)
WO (1) WO2007056405A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2416786A1 (en) * 2009-04-10 2012-02-15 Cypress Pharmaceutical, Inc. Phosphate-binding magnesium salts and uses thereof
US8247000B2 (en) 2009-04-10 2012-08-21 Cypress Pharmaceutical, Inc. Phosphate-binding magnesium salts and uses thereof
CN103159880B (zh) * 2011-12-14 2016-06-22 上海亿法医药科技有限公司 碳酸司维拉姆的制备方法
US9394318B2 (en) 2012-11-30 2016-07-19 Cypress Pharmaceuticals, Inc. Crystal polymorph of magnesium glycinate dihydrate and process for its preparation
RS59033B1 (sr) 2013-06-05 2019-08-30 Tricida Inc Polimeri koji vezuju protone za oralnu primenu
DK3593808T3 (da) * 2014-12-10 2021-02-01 Tricida Inc Proton-bindingspolymerer til oral indgivelse
US9649335B1 (en) * 2016-03-30 2017-05-16 Baylor University Intravenous administration of an oxygen-enabled fluid
CN116211887A (zh) 2016-05-06 2023-06-06 特里赛达公司 用于治疗酸碱失衡的组合物
JP6792640B2 (ja) 2016-12-28 2020-11-25 富士フイルム株式会社 窒素原子含有ポリマー又はその塩の乳化液、その製造方法、及び粒子の製造方法
TW201922249A (zh) * 2017-09-29 2019-06-16 日商第一三共股份有限公司 二羧酸化合物與磷吸附劑之組合
WO2019078197A1 (ja) * 2017-10-16 2019-04-25 富士フイルム株式会社 高リン血症治療剤
US11266684B2 (en) 2017-11-03 2022-03-08 Tricida, Inc. Compositions for and method of treating acid-base disorders

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2456428A (en) * 1944-10-11 1948-12-14 Shell Dev Polyallyl amine and related polymeric amines
US3104205A (en) * 1959-12-17 1963-09-17 Warner Lambert Pharmaceutical Deodorant composition comprising the copper complex of the copolymer of allylamine and methacrylic acid
US3308020A (en) * 1961-09-22 1967-03-07 Merck & Co Inc Compositions and method for binding bile acids in vivo including hypocholesteremics
US3332841A (en) * 1961-10-04 1967-07-25 Lilly Co Eli Method of treating hyperacidity
US3624209A (en) * 1966-12-28 1971-11-30 Bristol Myers Co Composition for treatment of gastro-intestinal disorders
US3980770A (en) * 1971-06-04 1976-09-14 Pharmacia Aktiebolag Polymerization products containing amino groups useful in serum cholesterol level control
US4205064A (en) * 1973-06-11 1980-05-27 Merck & Co., Inc. Bile acid sequestering composition containing poly[{alkyl-(3-ammoniopropyl)imino}-trimethylenedihalides]
US4181718A (en) * 1975-12-29 1980-01-01 Mason Norbert S Polyanion-stabilized aluminum hydrogels
US4071478A (en) * 1976-06-07 1978-01-31 Merck & Co., Inc. Controlled partially cross-linked 3,3-ionenes
US4143130A (en) * 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4247393A (en) * 1979-01-11 1981-01-27 Wallace Richard A Hemodialysis assist device
US4344993A (en) * 1980-09-02 1982-08-17 The Dow Chemical Company Perfluorocarbon-polymeric coatings having low critical surface tensions
US4504640A (en) * 1982-05-19 1985-03-12 Nitto Boseki Co., Ltd. Process for producing monoallylamine polymer
DE3241113A1 (de) * 1982-11-06 1984-05-10 Bayer Ag, 5090 Leverkusen Vakzinen mit zuschlagstoffen
JPS6090243A (ja) * 1983-10-25 1985-05-21 Nitto Boseki Co Ltd 小球状モノアリルアミン橋かけ重合体の製造方法
US4540760A (en) * 1984-01-11 1985-09-10 Nitto Boseki Co. Ltd. Process for producing polymers of monoallylamine
DE3402878A1 (de) * 1984-01-27 1985-08-01 Algina AG, Zug Arzneimittel und die verwendung schwerloeslicher calcium- und/oder magnesiumverbindungen als arzneimittel
US4631305A (en) * 1985-03-22 1986-12-23 The Upjohn Company Polymeric material as a disintegrant in a compressed tablet
DE3541511A1 (de) * 1985-11-19 1987-05-21 Grace W R Ab Promoter fuer die papierleimung, verfahren zu dessen herstellung und dessen verwendung
US6274713B1 (en) * 1989-04-07 2001-08-14 Salutar, Inc. Polychelants
US5236701A (en) * 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
US5053423A (en) * 1990-03-22 1991-10-01 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
US5055197A (en) * 1991-04-05 1991-10-08 Rohm And Haas Company Process for removing residual monomers and oligemers from amine-containing polymers
US5108767A (en) * 1991-06-10 1992-04-28 Abbott Laboratories Liquid nutritional product for persons receiving renal dialysis
EP0580078B1 (de) * 1992-07-22 1997-10-15 Hoechst Aktiengesellschaft Hydrophile Zentren aufweisende Polyvinylamin-Derivate, Verfahren zu ihrer Herstellung sowie die Verwendung der Verbindungen als Arzneimittel, Wirkstoffträger und Nahrungsmittelhilfsstoff
EP0580079B1 (de) * 1992-07-22 1996-12-11 Hoechst Aktiengesellschaft Vernetzte, stickstoffhaltige Vinylcopolymere, Verfahren zu ihrer Herstellung sowie die Verwendung dieser Verbindungen
US5302531A (en) * 1992-10-22 1994-04-12 Miles Inc. Composition for the semiquantitative determination of specific gravity of a test sample
US5487888A (en) * 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5929184A (en) * 1993-06-02 1999-07-27 Geltex Pharmaceuticals, Inc. Hydrophilic nonamine-containing and amine-containing copolymers and their use as bile acid sequestrants
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) * 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5414068A (en) * 1994-01-24 1995-05-09 Rohm And Haas Company Crosslinked anion exchange particles and method for producing the particles
WO1998003185A1 (fr) * 1996-07-19 1998-01-29 Nikken Chemicals Co., Ltd. Remedes contre l'hyperphosphatemie
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US6566407B2 (en) * 1997-11-05 2003-05-20 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6410616B1 (en) * 1998-04-09 2002-06-25 Nippon Shokubai Co., Ltd Crosslinked polymer particle and its production process and use
DE19835467A1 (de) * 1998-08-06 2000-02-17 Elenac Gmbh Feststoffreaktor mit antistatischer Beschichtung zur Durchführung von Reaktionen in der Gasphase
DE19917705C1 (de) * 1999-04-20 2000-12-28 Vitasyn Gmbh Mittel zur Therapie von Hyperphosphatämie
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
US6733780B1 (en) * 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
JP4265911B2 (ja) * 2000-07-28 2009-05-20 エフ．ホフマン−ラ ロシュ アーゲー 新規医薬組成物
WO2002085379A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for improving vascular access in patients with vascular shunts
CA2444046C (en) * 2001-04-18 2011-06-07 Steven K. Burke Use of colesevelam in reducing serum glucose
BR0209133A (pt) * 2001-04-18 2004-06-15 Genzyme Corp Método para tratar gota e para reduzir os nìveis de ácido úrico n0 sangue
WO2002085380A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for treating gout and reducing serum uric acid
JP4303595B2 (ja) * 2001-12-21 2009-07-29 透 小池 アニオン性置換基を有する物質を捕捉可能な亜鉛錯体
US20040115265A1 (en) * 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
WO2004085448A2 (en) * 2003-03-19 2004-10-07 Genzyme Corporation Unsaturated phosphinyl-phosphonate phosphate transport inhibitors
AU2004311849B2 (en) * 2003-12-31 2009-04-02 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
US7019085B2 (en) * 2004-08-30 2006-03-28 Albright Robert L Phosphate selective resin and related methods
US7985418B2 (en) * 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
US20060177415A1 (en) * 2004-11-01 2006-08-10 Burke Steven K Once a day formulation for phosphate binders

Also Published As

Publication number Publication date
CA2626734A1 (en) 2007-05-18
JP2009514966A (ja) 2009-04-09
WO2007056405A3 (en) 2007-11-08
EP1945196A2 (en) 2008-07-23
WO2007056405A2 (en) 2007-05-18
WO2007056405A8 (en) 2007-08-02
US20090162314A1 (en) 2009-06-25
BRPI0618352A2 (pt) 2011-08-23
CN101304739A (zh) 2008-11-12

Similar Documents

Publication Publication Date Title
AR060690A1 (es) Polimeros que contienen magnesio para la hiperfosfatemia
ECSP056127A (es) Inhibidores de 3-quinasa de fosfatidil-inositol
BRPI0410477A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto
CY1109970T1 (el) Παραγωγα 6-11 δικυκλικου κετολιδιου
AR065806A1 (es) Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea.
BRPI0911476A2 (pt) compostos ativadores de glicoquinase de piridazinona, composição farmaceutica, uso dos compostos, método para tratamento de uma enfermidade e/ou distúbio metabólico e processo para a preparação dos compostos
BRPI0406717A (pt) Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção
BRPI0516454A (pt) compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, sua utilização, método para o tratamento e profilaxia de enfermidades, e de diabetes do tipo ii
MX2010003868A (es) Cis-imidazolinas quirales.
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
TW200634021A (en) 3,6-bicyclolides
TW200730511A (en) Chroman compounds
RU2015122032A (ru) Оксазолидинонсодержащие соединения, композиции и способы их использования
GEP20125548B (en) New dihidroindolone compounds, a process for its preparation and pharmaceutical compositions containing them
GEP20115166B (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
WO2005000863A3 (en) 6, 11-4c-bicyclic 9a-azalide derivatives
TW200730510A (en) Chroman compounds
BRPI0511535A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou pró-droga do mesmo, pró-droga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto ou um sal farmaceuticamente aceitável, ou éster hidrolisável in-vivo do mesmo, ou de um seu éster hidrolisável in vivo, composição farmacêutica, e, processo para a preparação de um composto ou sais farmaceuticamente aceitáveis ou ésteres hidrolisáveis in-vivo do mesmo
BR0315801A (pt) Compostos piridopirimidinona, eu processo de preparação e as composições farmacêuticas que os contêm
US10077284B2 (en) UBA5 inhibitors
AR046318A1 (es) Sales de tiotropio, procedimientos para su preparacion y composiciones farmaceuticas que las contienen.
GEP20084470B (en) New phenylpyridinylpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them
AR036176A1 (es) Un derivado de fenil-acetamido-tiazol, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un producto o kit que los comprende, y un metodo que utiliza dicho derivado
ES2540327T3 (es) Derivados de 8-hidroxiquinolin-7-carboxamida terciaria y usos de los mismos
BRPI0712312A2 (pt) Composto, processo para a produção do mesmo, composição farmacêutica, agente antimicrobiano, agente anti-mrsa, método para a prevenção ou o tratamento de uma doença infecciosa, e, uso do composto

Legal Events

Date Code Title Description
FB Suspension of granting procedure